Application of atorvastatin in coronar heart disease females suffering from essential arterial hypertension in postmenopause

The report looks at the results of applying atorvastatin to treat lipid metabolism disorders in coronary heart disease (CHD) females suffering from essential arterial hypertension (AHT) in postmenopause. 110 females with CHD and essential AHT of II and III class were studied in postmenopause. The control group included 30 females being in postmenopause but not suffering from AHT. The experimental group consisted of 35 females in their fertile period suffering from essential AHT of II and III class. A menopause is known to be closely related with considerable changes in the lipid profile, such as an increase in the total cholesterol level (TCL), low-density lipoproteins (LDLP) and very low-density lipoproteins (VLDLP), as well as a decrease in high-density lipoproteins (HDLP). After 3 months of complex treatment with atorvastatin, positive changes in lipid metabolism were observed in all females with the preserved menstrual function, while in those females who were in postmenopause these changes tended to be insignificant. Most likely this fact demonstrates that there is no mediated influence of estrogens on the lipid profile because of the decrease in TCL and LDLP levels and the increase in LDLP level. Thus, the probability of AHT and CHD, as well as atherosclerosis progression in this group of females considerably increases.